Urology Times staff

Dr. Gregg Eure, MD, FACS, Urology of Virginia, discusses a survey of approximately 1000 men aged ≥45 years with BPH (≥1 voiding symptom) who answered questions about their urinary symptoms. Over 45% of the surveyed men reported that urinary symptoms led them to avoid events or activities they enjoy. Many men reported nocturia, with 70% of respondents overall indicating that nocturia has affected their energy level. Almost one-fourth (about 22%) of the men reported sleeping in another room than their spouse/partner/significant other to avoid disturbing them with their nighttime bathroom use. Teleflex Incorporated conducted the survey.

Videos

Nearly half of the surveyed men reported that urinary symptoms led them to avoid events or activities they enjoy. 

Dr. Eure discusses survey results of BPH impact on patient QOL

In a video filmed during the 2021 ASCO Annual Meeting,

shares notable findings from the abstract, “Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle-invasive bladder cancer (MIBC): HCRN GU 16-257,” for which he served as a study author. Galsky is Professor of Medicine (Hematology and Medical Oncology) and Acting Chief of the Division of Hematology and Medical Oncology for the Mount Sinai Health System, New York City, New York.

“The complete clinical response rate of 48% was somewhat surprising, although consistent with our assumptions in terms of the statistical design of the study,” says Matthew Galsky, MD.

Dr. Galsky discusses key findings from phase 2 trial of MIBC regimen

 discusses why she began posting urology-related content on social media and shares how her content is received by patients. Pearlman is a clinical assistant professor and Men's Health Program Director at the University of Iowa, Iowa City.

Urologist Amy M. Pearlman, MD, discusses how she uses social platforms such as Twitter, Facebook, and Tiktok to entertain and inform.

Dr. Pearlman discusses her experiences with social media

Michael Devitt, MD, a hematologist/oncologist and assistant professor at the University of Virginia Medical Center, discusses whether circulating tumors cells are ready for primetime as a diagnostic/prognostic biomarker in urothelial carcinoma.

Genomic testing has becoming increasingly critical in bladder cancer, as the FDAapproves novel targeted agents specifically for patients with certain genetic alterations. For example, erdafitinib (Balversa) is approved by the FDA for the treatment of patients with locally advanced or metastatic urothelial carcinoma, with susceptible 

Dr. Michael Devitt, discusses whether circulating tumors cells are ready for primetime as a diagnostic/prognostic biomarker in urothelial carcinoma.

Urology Times staff

Articles

Dr. Eure discusses survey results of BPH impact on patient QOL

Dr. Galsky discusses key findings from phase 2 trial of MIBC regimen

Dr. Pearlman discusses her experiences with social media

Dr. Devitt on circulating tumor cells in bladder cancer